NASDAQ:AIDX 20/20 Biolabs (AIDX) Stock Price, News & Analysis $0.16 -0.02 (-13.01%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.16 +0.01 (+5.03%) As of 11/20/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About 20/20 Biolabs Stock (NASDAQ:AIDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 20/20 Biolabs alerts:Sign Up Key Stats Today's Range$0.16▼$0.1850-Day Range$0.16▼$0.5252-Week Range$0.16▼$50.00Volume301,482 shsAverage Volume230,171 shsMarket Capitalization$2.10 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview 20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.AI Generated. May Contain Errors. Read More 20/20 Biolabs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreAIDX MarketRank™: 1.75855780022 of 5 stars20/20 Biolabs scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus Rating20/20 Biolabs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside Potential20/20 Biolabs has a consensus price target of $5.00, representing about 3,082.7% upside from its current price of $0.16.Amount of Analyst Coverage20/20 Biolabs has only been the subject of 1 research reports in the past 90 days.Read more about 20/20 Biolabs' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 20/20 Biolabs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 20/20 Biolabs is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio20/20 Biolabs has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.59% of the float of 20/20 Biolabs has been sold short.Short Interest Ratio / Days to Cover20/20 Biolabs has a short interest ratio ("days to cover") of 0.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 20/20 Biolabs has recently increased by 405.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield20/20 Biolabs does not currently pay a dividend.Dividend Growth20/20 Biolabs does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News Sentiment20/20 Biolabs has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for 20/20 Biolabs this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AIDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 20/20 Biolabs insiders have not sold or bought any company stock.Percentage Held by Insiders27.66% of the stock of 20/20 Biolabs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20/20 Biolabs has minimal institutional ownership at this time.Read more about 20/20 Biolabs' insider trading history. Receive AIDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 20/20 Biolabs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIDX Stock News Headlines20/20 Biolabs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 17, 2026 | marketscreener.comM20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business UpdatesNovember 16, 2026 | globenewswire.comPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026November 5, 2026 | finance.yahoo.com20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth StrategyOctober 29, 2026 | globenewswire.com20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026October 2, 2026 | globenewswire.com20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise ModelSeptember 29, 2026 | globenewswire.com20/20 Biolabs Inc (AIDX)September 19, 2026 | investing.comSee More Headlines AIDX Stock Analysis - Frequently Asked Questions How have AIDX shares performed this year? 20/20 Biolabs' stock was trading at $3.39 on March 2, 2026. Since then, AIDX shares have decreased by 95.4% and is now trading at $0.1571. How were 20/20 Biolabs' earnings last quarter? 20/20 Biolabs Inc (NASDAQ:AIDX) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business earned $380.22 thousand during the quarter. 20/20 Biolabs had a negative trailing twelve-month return on equity of 539.40% and a negative net margin of 317.83%. When did 20/20 Biolabs IPO? 20/20 Biolabs (AIDX) raised $0 in an initial public offering (IPO) on Thursday, February 19th 2026. The company issued 15,164,724 shares at a price of $0.00 per share. How do I buy shares of 20/20 Biolabs? Shares of AIDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:AIDX CIK1139685 Web2020biolabs.com Phone(240) 453-6339FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Price Target for 20/20 Biolabs$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+3,082.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.74 million Net Margins-317.83% Pretax Margin-317.83% Return on Equity-539.40% Return on Assets-120.73% Debt Debt-to-Equity RatioN/A Current Ratio1.62 Quick Ratio1.95 Sales & Book Value Annual Sales$2.05 million Price / Sales1.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book3.14Miscellaneous Outstanding Shares13,370,000Free Float9,670,000Market Cap$2.10 million OptionableN/A BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:AIDX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 20/20 Biolabs Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share 20/20 Biolabs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.